- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02177253
Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease
June 26, 2014 updated by: Boehringer Ingelheim
A Comparison of Ipratropium Bromide/Salbutamol (40 mcg / 200 mcg, One Inhalation) Delivered by the Respimat ® Inhaler to COMBIVENT Inhalation Aerosol (Two Inhalations), Ipratropium Bromide Respimat ® and Placebo of Each Formulation in a 12-week, Double-blind, Safety and Efficacy Study in Adults With Chronic Obstructive Pulmonary Disease
The primary objective of this study was to compare the long-term (12-week) bronchodilator efficacy and safety of ipratropium bromide / salbutamol combination administered by the Respimat® 40 mcg / 200 mcg (one inhalation q.i.d.) to COMBIVENT Inhalation Aerosol (two inhalations q.i.d.), ipratropium bromide Respimat® (one inhalation q.i.d.) and Placebo formulations of each in patients with Chronic Obstructive Pulmonary Disease (COPD).
An additional objective was to show the superiority of Combivent Respimat as compared to ipratropium bromide (40 mcg) Respimat.
Steady state pharmacokinetics over one dosing interval following four weeks of therapy were also characterized.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
1118
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
All patients must have a diagnosis of COPD and the following spirometric criteria:
- Visit 1 (Screening) and Visit 2: Patients must have relatively stable, moderate to severe airway obstruction with an FEV1 ≤65% of predicted normal and FEV1 ≤70% of FVC
- Male or female patients 40 years of age or older
- Patients must have a smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year
- Patients must be able to perform pulmonary function tests and maintain records during the study period as required in the protocol
- Patients must be able to be trained in the proper use of an MDI (metered dose inhaler) and the Respimat® inhaler
- All patients must sign an Informed Consent Form prior to participation in the trial
Exclusion Criteria:
- Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
- Patients with clinically relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
- All patients with a SGOT (serum glutamic oxaloacetic transaminase) >80 IU/L, SGPT (serum glutamic pyruvic transaminase) >80 IU/L, bilirubin >2.0 mg/dL or creatinine >2.0 mg/dL will be excluded regardless of the clinical condition
- Patients who have a total blood eosinophil count ≥600/mm3
- Patients with a recent history (i.e., one year or less) of myocardial infarction
- Patients with a recent history (i.e., three years or less) of heart failure or patients with any cardiac arrhythmia requiring drug therapy
- Patients with a history of cancer, other than treated basal cell carcinoma, within the last 5 years
- Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis
- Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of a thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1
- Patients with a history of asthma or allergic rhinitis
- Patients with a history of and/or active alcohol or drug abuse
- Patients with known active tuberculosis
- Patients with an upper or lower respiratory tract infection or COPD exacerbation in the 6 weeks prior to the Screening Visit (Visit 1) or during the baseline period
- Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction
- Patients with known narrow-angle glaucoma
- Patients with current significant psychiatric disorders
- Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy
- Patients who are being treated with cromolyn sodium or nedocromil sodium
- Patients who are being treated with antihistamines for any excluded allergic conditions
- Patients using oral corticosteroid medication at unstable doses (i.e., less than 6 weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day
- Patients who initiated use of an inhaled steroid or changed doses less than 6 weeks prior to the Screening Visit (Visit 1) or during the baseline period
- Patients who are being treated with beta-blocker medications, MAO (monoamine oxidase) inhibitors or tricyclic antidepressants. Beta blocker eye medications (e.g., Betoptic) for treatment of non-narrow angle glaucoma are allowed
- Patients who have had changes in their therapeutic plan within the last 6 weeks prior to the Screening Visit (Visit 1) or during the baseline period
- Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
- Patients with known hypersensitivity to anticholinergic drugs or any component of the ipratropium bromide/salbutamol Respimat® solution (including BAC (Benzalkonium chloride) and EDTA (Ethylenediaminetetraacetic acid)) or the ipratropium bromide/salbutamol MDI components
- Previous participation in this study
- Patients who are currently participating in another study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ipratropium bromide / Salbutamol Inhalation solution
|
|
Placebo Comparator: Placebo Inhalation solution
|
|
Experimental: Ipratropium bromide Inhalation solution
|
|
Active Comparator: COMBIVENT Inhalation Aerosol (ipratropium bromide/salbutamol)
|
|
Placebo Comparator: Placebo Inhalation Aerosol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
FEV1 TAUC0-6 (Total area under the FEV1 (forced expiratory volume in one second) curve from 0 to 6 hours divided by six)
Time Frame: Day 85
|
Day 85
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
FEV1 TAUC0-6
Time Frame: Days 1, 29 and 57
|
Days 1, 29 and 57
|
FEV1 TAUC0-8
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
Peak FEV1 post treatment over two hours
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
Change from baseline in Peak FEV1 response
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
Area under the FEV1 curve from 0 to 6 hours above test-day baseline divided by six for normalization (AUC0-6)
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
Onset of therapeutic FEV1 response
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
Duration of therapeutic FEV1 response
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
Time to peak FEV1 response
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
TAUC0-6, TAUC0-8 and peak FVC (Forced vital capacity)
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
Amount of beta agonist therapy used as rescue medication during the treatment period
Time Frame: up to day 85
|
up to day 85
|
Number of patients using concomitant medication including corticosteroids during the treatment period
Time Frame: up to day 85
|
up to day 85
|
Weekly means of daily symptom scores over the treatment period
Time Frame: up to day 85
|
up to day 85
|
Number of patients with at least one COPD exacerbation
Time Frame: up to day 85
|
up to day 85
|
Number of COPD exacerbations during the treatment period
Time Frame: up to day 85
|
up to day 85
|
Physician's Global Evaluation
Time Frame: Days 1, 29, 57 and 85
|
Days 1, 29, 57 and 85
|
Trough PEFR (peak expiratory flow rate) measured by the patient at home once daily
Time Frame: up to day 85
|
up to day 85
|
Number of patients with adverse events
Time Frame: up to day 85
|
up to day 85
|
Incidence of paradoxical bronchoconstriction on the test day
Time Frame: up to day 85
|
up to day 85
|
Number of COPD exacerbation days
Time Frame: up to day 85
|
up to day 85
|
Number of patients with clinically significant changes in vital signs
Time Frame: Baseline, days 1, 29, 57 and 85
|
Baseline, days 1, 29, 57 and 85
|
Number of patients with abnormal changes in laboratory parameters
Time Frame: Days 29 and 85
|
Days 29 and 85
|
Number of patients with abnormal changes in 12-lead electrocardiogram (ECG) parameters
Time Frame: pre-treatment and 1 hour post-treatment on days 1, 29 and 85
|
pre-treatment and 1 hour post-treatment on days 1, 29 and 85
|
Plasma ipratropium and salbutamol concentrations
Time Frame: pre-treatment, 5, 15, 30 and 60 minutes and 2, 4 and 8 hours after inhalation of test drug on day 29
|
pre-treatment, 5, 15, 30 and 60 minutes and 2, 4 and 8 hours after inhalation of test drug on day 29
|
Renal excretion amounts of ipratropium and salbutamol
Time Frame: 0-2 hours, 2-8 hours at day 29
|
0-2 hours, 2-8 hours at day 29
|
Length of COPD exacerbations during the treatment period
Time Frame: up to day 85
|
up to day 85
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2002
Primary Completion (Actual)
March 1, 2004
Study Registration Dates
First Submitted
June 20, 2014
First Submitted That Met QC Criteria
June 26, 2014
First Posted (Estimate)
June 27, 2014
Study Record Updates
Last Update Posted (Estimate)
June 27, 2014
Last Update Submitted That Met QC Criteria
June 26, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Adrenergic Agonists
- Anticonvulsants
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Albuterol
- Bromides
- Ipratropium
Other Study ID Numbers
- 1012.46
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Ipratropium bromide / Salbutamol
-
Hat Yai Medical Education CenterRecruitingAsthma | Airway Obstruction | Airway Remodeling | Parasympathetic Nervous System DiseasesThailand
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Assistance Publique - Hôpitaux de ParisWithdrawnPulmonary Arterial Hypertension
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Laval UniversityInstitut universitaire de cardiologie et de pneumologie de Québec, University...UnknownChronic Obstructive Pulmonary DiseaseCanada
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
The First Affiliated Hospital of Guangzhou Medical...RecruitingChronic Obstructive Pulmonary DiseaseChina
-
ThromboGenicsTerminatedArterial Occlusive DiseasesBelgium
-
ThromboGenicsBacchus VascularTerminatedDeep Vein ThrombosisIreland